GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascendis Pharma A/S (BSP:A1SN34) » Definitions » Cyclically Adjusted PS Ratio

Ascendis Pharma A/S (BSP:A1SN34) Cyclically Adjusted PS Ratio : 138.34 (As of Jun. 02, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Ascendis Pharma A/S Cyclically Adjusted PS Ratio?

As of today (2024-06-02), Ascendis Pharma A/S's current share price is R$48.42. Ascendis Pharma A/S's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was R$0.35. Ascendis Pharma A/S's Cyclically Adjusted PS Ratio for today is 138.34.

The historical rank and industry rank for Ascendis Pharma A/S's Cyclically Adjusted PS Ratio or its related term are showing as below:

BSP:A1SN34' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 111.05   Med: 136.25   Max: 170.19
Current: 123.71

During the past years, Ascendis Pharma A/S's highest Cyclically Adjusted PS Ratio was 170.19. The lowest was 111.05. And the median was 136.25.

BSP:A1SN34's Cyclically Adjusted PS Ratio is ranked worse than
96.63% of 504 companies
in the Biotechnology industry
Industry Median: 5.425 vs BSP:A1SN34: 123.71

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Ascendis Pharma A/S's adjusted revenue per share data for the three months ended in Mar. 2024 was R$9.125. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is R$0.35 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Ascendis Pharma A/S Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Ascendis Pharma A/S's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascendis Pharma A/S Cyclically Adjusted PS Ratio Chart

Ascendis Pharma A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 131.76

Ascendis Pharma A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 171.34 127.74 120.33 131.76 138.39

Competitive Comparison of Ascendis Pharma A/S's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Ascendis Pharma A/S's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascendis Pharma A/S's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascendis Pharma A/S's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Ascendis Pharma A/S's Cyclically Adjusted PS Ratio falls into.



Ascendis Pharma A/S Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Ascendis Pharma A/S's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=48.42/0.35
=138.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascendis Pharma A/S's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Ascendis Pharma A/S's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=9.125/118.4000*118.4000
=9.125

Current CPI (Mar. 2024) = 118.4000.

Ascendis Pharma A/S Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 1.101 99.700 1.308
201409 0.578 99.700 0.686
201412 0.544 99.400 0.648
201503 0.290 100.200 0.343
201506 0.283 100.300 0.334
201509 0.378 100.200 0.447
201512 0.332 99.800 0.394
201603 0.206 100.200 0.243
201606 0.174 100.600 0.205
201609 0.169 100.200 0.200
201612 0.120 100.300 0.142
201703 0.038 101.200 0.044
201706 0.051 101.200 0.060
201709 0.050 101.800 0.058
201712 0.030 101.300 0.035
201803 0.003 101.700 0.003
201806 0.002 102.300 0.002
201809 0.002 102.400 0.002
201812 1.104 102.100 1.280
201903 0.542 102.900 0.624
201906 0.296 102.900 0.341
201909 0.214 102.900 0.246
201912 0.239 102.900 0.275
202003 0.250 103.300 0.287
202006 0.174 103.200 0.200
202009 0.333 103.500 0.381
202012 0.063 103.400 0.072
202103 0.093 104.300 0.106
202106 0.115 105.000 0.130
202109 0.127 105.800 0.142
202112 0.551 106.600 0.612
202203 0.660 109.900 0.711
202206 0.589 113.600 0.614
202209 1.422 116.400 1.446
202212 2.274 115.900 2.323
202303 3.339 117.300 3.370
202306 4.433 116.400 4.509
202309 4.499 117.400 4.537
202312 13.008 116.700 13.197
202403 9.125 118.400 9.125

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Ascendis Pharma A/S  (BSP:A1SN34) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Ascendis Pharma A/S Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Ascendis Pharma A/S's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Ascendis Pharma A/S (BSP:A1SN34) Business Description

Traded in Other Exchanges
Address
Tuborg Boulevard 12, Hellerup, DNK, DK-2900
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.

Ascendis Pharma A/S (BSP:A1SN34) Headlines

No Headlines